Berna Biotech shareholders created the prerequisite to accept the public exchange offer of Crucell
The extraordinary general meeting of Berna Biotech, held in Berne, created the prerequisite to accept the public exchange offer of Crucell. It approved with about 90 percent of the represented shares the removal of the transfer restrictions. In addition, the shareholder's meeting elected Dr. Ronald Brus, CEO of Crucell N.V., Leonhard Kruimer, CFO of Crucell N.V. and Prof. Dr. Jaap Goudsmit, CSO of Crucell N.V. to the Berna Biotech Board of Directors. They replace the retiring members of the Board of Directors, Ulrich A. Ammann, Dr. Peter Grogg, Jürg Legler and Prof. Dr. Urs B. Schaad. The decisions will only come into force if the public exchange offer of Crucell will suceed.
The Board of directors again encouraged the shareholders to accept the public offer of Crucell. The time limit for tendering the shares will expire on January 20, 2006.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.